Pharvaris (NASDAQ:PHVS) CFO David Nassif Sells 10,000 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) CFO David Nassif sold 10,000 shares of Pharvaris stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $30.31, for a total transaction of $303,100.00. Following the sale, the chief financial officer owned 120,300 shares in the company, valued at approximately $3,646,293. This trade represents a 7.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Pharvaris Stock Performance

Shares of Pharvaris stock opened at $29.88 on Wednesday. The firm’s 50-day simple moving average is $28.61 and its 200-day simple moving average is $26.96. Pharvaris N.V. has a twelve month low of $15.46 and a twelve month high of $33.33. The firm has a market cap of $1.95 billion, a P/E ratio of -9.40 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.12. On average, equities analysts forecast that Pharvaris N.V. will post -3.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pharvaris

Institutional investors have recently modified their holdings of the stock. Tudor Investment Corp ET AL bought a new position in shares of Pharvaris in the third quarter worth about $1,943,000. Patient Square Capital LP raised its stake in shares of Pharvaris by 41.4% in the third quarter. Patient Square Capital LP now owns 345,381 shares of the company’s stock worth $8,617,000 after acquiring an additional 101,098 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Pharvaris by 710.4% in the third quarter. JPMorgan Chase & Co. now owns 27,085 shares of the company’s stock worth $676,000 after acquiring an additional 23,743 shares during the last quarter. Integral Health Asset Management LLC bought a new position in shares of Pharvaris in the third quarter worth about $4,990,000. Finally, Boothbay Fund Management LLC raised its stake in shares of Pharvaris by 735.1% in the third quarter. Boothbay Fund Management LLC now owns 135,181 shares of the company’s stock worth $3,373,000 after acquiring an additional 118,994 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts have commented on PHVS shares. Wolfe Research started coverage on shares of Pharvaris in a research report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price target on the stock. Wedbush boosted their price target on shares of Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Citigroup restated a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. Finally, Royal Bank Of Canada reduced their price target on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research report on Monday, April 6th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $49.18.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.